Assessing allergenicity of GM plants: new EFSA guidance provides advice
EFSA has published supplementary guidance on allergenicity to further strengthen risk assessment of genetically modified (GM) plants.
The document considers new scientific and regulatory developments, complementing recommendations in existing guidance and regulations.
What are the key points?
The new guidance relates to three particular areas.
Non-IgE-mediated adverse immune reactions to food comprise a large group of diseases, mostly occurring during childhood. Celiac disease is currently the best characterised of these diseases and therefore the only condition of this type covered by the guidance. The guidance provides detailed advice on how to assess the risk of novel proteins in GM plants causing celiac disease.
In vitro digestibility tests provide valuable information on how a newly created protein in a GM plant behaves during digestion, an important part of the overall safety assessment. The new guidance suggests refinements in the way current in vitro tests are conducted and proposes to evaluate their added value during a two-year interim period.
The assessment of endogenous allergenicity ensures the genetic modification does not adversely affect the levels of existing allergens in the GM plant compared to its conventional counterpart. This guidance document provides detailed additional information on how to address this requirement.
Successful conclusion of pilot project
The publication of this guidance document brings a two year-long pilot project to a successful conclusion. EFSA’s aim was to increase engagement with stakeholders in its scientific processes as part of the Open EFSA initiative.
An eight-member focus group acted as the consultative body throughout the development of this document. All parties involved agreed that the scientific process benefited from this inclusive approach.
- Guidance on allergenicity assessment of genetically modified plants
- Outcome of the public consultation on the draft guidance on allergenicity assessment of genetically modified plants
Notes to editors:
Immunoglobulin E (IgE) is a type of antibody produced by the immune system in response to an allergen. Non-IgE mediated immune reactions are those in which other mediators in the body are involved.
Latest News from
Security Union: EC presents new measures to better protect EU citizens19/10/2017 14:27:00
The EC has presented alongside its 11th Security Union Report a set of operational and practical measures to better defend EU citizens against terrorist threats and deliver a Europe that protects.
EU-U.S. Privacy Shield: First review shows it works but implementation can be improved19/10/2017 13:10:00
The EC has published its first annual report on the functioning of the EU- U.S. Privacy Shield, the aim of which is to protect the personal data of anyone in the EU transferred to companies in the U.S. for commercial purposes.
EC opens in-depth investigation into proposed merger of Celanese's and Blackstone's acetate tow activities18/10/2017 16:15:00
The EC has opened an in-depth investigation to assess the proposed creation of an acetate flake and acetate tow joint venture by Celanese and Blackstone under the EU Merger Regulation.
EU approves €100m in financial assistance for Jordan18/10/2017 14:10:00
The EC, on behalf of the EU, has approved the disbursement of a €100m loan to Jordan under its Macro-Financial Assistance (MFA) programme.